Showing results (81-90 of 176) with videos related to

Sort By:
Pageof 18
The EMBO Journal|August 2, 2011
Regulation of TFEB and V-ATPases by mTORC1Samuel Peña-Llopis, Silvia Vega-Rubin-de-Celis, Jacob C Schwartz, et al.
Molecular Cancer Research : MCR|July 30, 2011
Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinomaBlanka Kucejova, Samuel Peña-Llopis, Toshinari Yamasaki, et al.
Medrxiv : the Preprint Server for Health Sciences|December 3, 2025
Radiologic, Pathologic, and Deep Learning Predictors of Response to Immune Checkpoint Blockade in Renal Cell Carcinoma Patients Undergoing Post-Treatment NephrectomyPayal Kapur, Alana Christie, Vipul Jarmale, et al.
Cell Reports. Medicine|February 19, 2026
HIF-activated priming of TRAIL-induced cell death determines epigenetic vulnerability in kidney cancerYong Wang, Yan Xiong, Shuiqiao Liu, et al.
Science Immunology|February 23, 2020
Tumor neoantigenicity assessment with CSiN score incorporates clonality and immunogenicity to predict immunotherapy outcomesTianshi Lu, Shidan Wang, Lin Xu, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 7, 2020
Complement as Prognostic Biomarker and Potential Therapeutic Target in Renal Cell CarcinomaBritney Reese, Ashok Silwal, Elizabeth Daugherity, et al.
Medrxiv : the Preprint Server for Health Sciences|February 24, 2025
Prompts to Table: Specification and Iterative Refinement for Clinical Information Extraction with Large Language ModelsDavid Hein, Alana Christie, Michael Holcomb, et al.
Molecular and Cellular Biology|May 4, 2016
Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell CarcinomaTram Anh Tran, Hon Sing Leong, Andrea Pavia-Jimenez, et al.
BMC Urology|April 18, 2015
Prospective evaluation of plasma levels of ANGPT2, TuM2PK, and VEGF in patients with renal cell carcinomaBishoy A Gayed, Jessica Gillen, Alana Christie, et al.
Oncotarget|July 30, 2015
High-throughput simultaneous screen and counterscreen identifies homoharringtonine as synthetic lethal with von Hippel-Lindau loss in renal cell carcinomaNicholas C Wolff, Andrea Pavía-Jiménez, Vanina T Tcheuyap, et al.
Pageof 18